Knockdown of FGFR1 in patient-derived GBM cell lines reduced cell migration compared to non-targeting controls, whereas FGFR2 knockdown did not affect cell migration (Fig. 3A,B, S1B). The gene discussed is FGFR2; the disease is glioblastoma.